The forecast for the import of antisera and other blood fractions to the US shows a steady increase, with values predicted to rise from $18.329 billion in 2024 to $21.052 billion by 2028. Given that we are in 2024, these figures define the future trajectory of imports based on current data.

Year-on-year variations indicate a consistent growth pattern, with the import value increasing notably each year. Over the five-year span, the Compound Annual Growth Rate (CAGR) suggests a robust and steady expansion in the import sector.

Trends to watch for include:

Potential impacts of global economic conditions on import prices and volumes.
The evolution of healthcare policies affecting demand for biological products.
Technological advancements in blood fractionation and treatments boosting demand.
Fluctuations in international trade agreements and tariffs influencing import dynamics.